1. Home
  2. MNTS vs PHGE Comparison

MNTS vs PHGE Comparison

Compare MNTS & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Momentus Inc.

MNTS

Momentus Inc.

HOLD

Current Price

$4.93

Market Cap

10.0M

Sector

Industrials

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$5.20

Market Cap

9.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNTS
PHGE
Founded
2017
2015
Country
United States
Israel
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0M
9.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MNTS
PHGE
Price
$4.93
$5.20
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$26.00
AVG Volume (30 Days)
1.4M
1.7M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$286.00
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.25
52 Week High
$15.98
$8.50

Technical Indicators

Market Signals
Indicator
MNTS
PHGE
Relative Strength Index (RSI) 42.80 52.54
Support Level $5.21 $5.12
Resistance Level $6.14 $6.85
Average True Range (ATR) 0.80 0.93
MACD -0.16 -0.15
Stochastic Oscillator 15.48 50.89

Price Performance

Historical Comparison
MNTS
PHGE

About MNTS Momentus Inc.

Momentus Inc offers in-space infrastructure services by building transfer and service vehicles that carry satellites and hosted payloads between orbits in space. It is a provider of three critical functions, in the new space economy: Space Transportation, Satellite as a Service, and In-Orbit Servicing.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: